Cigna modified MM 0530 — its nucleic acid pathogen testing coverage policy — effective February 14, 2026. If your team bills any of the 72 CPT codes under this policy, your documentation and medical necessity criteria need to be current now.
This update from Cigna Healthcare covers nucleic acid infectious pathogen testing across a wide range of clinical settings: STD testing, respiratory infections, gastrointestinal pathogens, CNS infections, wound infections, vaginal infections, and more. The MM 0530 Cigna system covers codes ranging from CPT 87490 for Chlamydia trachomatis to CPT 0480U for metagenomic CSF testing — 72 codes in total, with 453 ICD-10-CM diagnosis codes attached. Panel testing is explicitly addressed. Inpatient testing and COVID-19 solo testing are not.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Cigna Healthcare |
| Policy | Nucleic Acid Pathogen Testing |
| Policy Code | MM 0530 |
| Change Type | Modified |
| Effective Date | February 14, 2026 |
| Impact Level | High |
| Specialties Affected | Infectious disease, OB/GYN, pulmonology, gastroenterology, neurology, urology, wound care, primary care, clinical labs |
| Key Action | Audit your charge capture for all 72 CPT codes under MM 0530 and confirm your documentation meets Cigna's medical necessity criteria before billing |
Cigna Nucleic Acid Pathogen Testing Coverage Criteria and Medical Necessity Requirements 2026
The core rule under this Cigna coverage policy is straightforward: all 72 CPT codes are considered medically necessary when criteria in the applicable coverage position are met. That phrase does a lot of work. It means the test alone doesn't justify coverage — the clinical context does.
Cigna's medical necessity standard under MM 0530 requires that the test be ordered for a specific clinical indication, tied to a documented infection or a reasonable suspicion of one. The 453 ICD-10-CM codes attached to this policy define the universe of covered indications. If your diagnosis code isn't in that list, your claim is at risk.
Panel testing — where a single test looks for multiple pathogens at once — is explicitly addressed in this policy. Cigna covers panel testing under the same medical necessity framework. But billing a panel when a single-pathogen test was clinically appropriate is exactly the kind of pattern that triggers audits. Document why the panel was necessary, not just what it found.
The policy specifically excludes two categories from its scope. First, nucleic acid testing for SARS-CoV-2 alone falls under Cigna coverage policy 0557 — not MM 0530. If your lab bills CPT 87636 or 87637 as part of a combo panel (flu/RSV/COVID), MM 0530 applies. If it's a solo COVID test, route that to policy 0557. Second, inpatient testing is not covered under this policy at all.
Prior authorization requirements are not explicitly called out in the policy summary, but given the breadth of codes — including several high-cost PLA codes like 0152U, 0323U, and 0480U — check your Cigna contract and the provider portal before assuming PA is waived. For PLA codes specifically, reimbursement rates vary significantly, and some plans require pre-service review.
Cigna Nucleic Acid Pathogen Testing Exclusions and Non-Covered Indications
Two hard exclusions apply under MM 0530.
Inpatient testing is outside this policy's scope entirely. If your team bills nucleic acid pathogen testing for patients at an inpatient level of care, a different policy applies. Confirm with your Cigna provider relations contact which policy governs inpatient molecular testing for your facility type.
Standalone COVID-19 nucleic acid testing is excluded. CPT 87636 (SARS-CoV-2/influenza A and B) and 87637 (SARS-CoV-2/influenza A and B/RSV) are covered under MM 0530 because they test multiple pathogens. But if your lab offers a test that only detects SARS-CoV-2, that claim belongs under policy 0557, not here. Billing it under MM 0530 will likely result in a claim denial.
Coverage Indications at a Glance
| Indication | Status | Relevant CPT Codes | Notes |
|---|---|---|---|
| STD testing (chlamydia, gonorrhea, trichomonas, syphilis) | Covered when criteria met | 87490–87492, 87494, 87590–87592, 87660, 87661, 0321U, 0371U, 0374U | Must link to appropriate ICD-10 (A54.xx, A56.xx, etc.) |
| HPV testing (high-risk, low-risk, types 16/18) | Covered when criteria met | 87623, 87624, 87625, 87626, 0463U, 0502U | Cervical cancer screening indications apply |
| Vaginal/vaginosis pathogen panels | Covered when criteria met | 87510–87512, 81513, 81514, 81515, 0330U, 0352U, 0557U, 0505U | Gardnerella, BV, vaginitis multiplex panels included |
| Herpes simplex / Varicella zoster | Covered when criteria met | 87528–87530, 0527U | Skin, mucous membrane, CNS indications |
| Respiratory pathogen panels | Covered when criteria met | 87631, 87633, 87636, 87637, 0115U, 0202U, 0223U, 0225U, 0240U, 0241U, 0373U, 0442U, 0528U, 0556U, 0563U, 0564U | COVID combo panels covered; solo COVID-19 test excluded |
| Gastrointestinal pathogen panels | Covered when criteria met | 87505, 87506, 87507, 0369U | Bacterial, viral, parasitic GI panels |
| CNS / CSF pathogen testing | Covered when criteria met | 87483, 0323U, 0480U | Meningitis, encephalitis, metagenomic NGS |
| Candida / fungal detection | Covered when criteria met | 87480–87482, 0140U | Skin, nail, systemic fungal infections |
| Wound infection panels | Covered when criteria met | 0370U, 0600U | Surgical wound, 34–65 organism panels |
| UTI / genitourinary pathogen testing | Covered when criteria met | 0504U, 0371U, 0372U, 0374U | Includes antibiotic resistance gene detection |
| Gram-positive / gram-negative blood culture identification | Covered when criteria met | 0141U, 0142U | Drug resistance element detection included |
| Broad-range / NOS nucleic acid testing | Covered when criteria met | 87797, 87798, 87799 | Not otherwise specified — requires specific clinical justification |
| Inpatient nucleic acid pathogen testing | Not covered under MM 0530 | All | Governed by separate inpatient policy |
| Standalone SARS-CoV-2 testing | Not covered under MM 0530 | Refer to policy 0557 | Use 87636/87637 only in combo panels here |
Cigna Nucleic Acid Pathogen Testing Billing Guidelines and Action Items 2026
| # | Action Item |
|---|---|
| 1 | Audit your charge capture against all 72 CPT codes in MM 0530 before February 14, 2026. Cross-reference your lab's active test menu against this list. If you bill any of these codes to Cigna, confirm your documentation supports medical necessity under the current criteria. |
| 2 | Map your ICD-10-CM codes to the 453 diagnosis codes Cigna accepts under this policy. A medically appropriate test billed with an unsupported diagnosis code will deny. Pull your Cigna-specific nucleic acid testing claims from the last 90 days and check the ICD-10 codes used. |
| 3 | Separate your COVID-19 billing now. If your lab bills CPT 87636 or 87637 as part of a respiratory combo panel, those stay under MM 0530. If your lab also bills a standalone COVID-19 test, that claim must go under policy 0557. Mixing these up is the fastest path to a claim denial under the new policy language. |
| 4 | Flag your high-cost PLA codes for prior authorization review. Codes like 0152U, 0323U, 0480U, 0480U, and 0600U represent high-reimbursement tests. Contact your Cigna provider relations team to confirm whether any of these require prior auth under your specific plan contracts. Don't assume PA is waived because the code appears on the covered list. |
| 5 | Document medical necessity for every panel test, not just single-pathogen tests. Cigna's language makes clear that panel testing is covered — but only when criteria are met. That means your ordering documentation needs to show why the panel was necessary, not just a list of results. Urine culture + a UTI code won't cut it for a 17-pathogen panel like CPT 0504U. Your provider's note needs to support the breadth of testing ordered. |
| 6 | Do not bill inpatient nucleic acid testing under MM 0530. If your facility bills for both inpatient and outpatient molecular testing, make sure your billing team knows which policy governs each setting. Inpatient claims billed under MM 0530 will deny. |
| 7 | Review your PLA code billing guidelines for new codes in this update. Several newer PLA codes appear in this policy — including 0527U, 0528U, 0531U, 0556U, 0557U, 0563U, 0564U, 0600U, and 0502U. If your lab recently added any of these to your test menu, confirm they're set up correctly in your charge master with the right payer-specific modifiers and diagnosis linkage. |
If your lab bills high volumes of nucleic acid panels to Cigna — particularly GI panels, respiratory panels, or wound infection panels — loop in your compliance officer before the effective date. The combination of 72 CPT codes, 453 ICD-10 codes, and multiple PLA codes creates real audit exposure if your documentation or coding isn't tight.
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Nucleic Acid Pathogen Testing Under MM 0530
Covered CPT Codes (When Medical Necessity Criteria Are Met)
| Code | Description |
|---|---|
| 0112U | Infectious agent detection and identification, targeted sequence analysis (16S and 18S rRNA genes) |
| 0115U | Respiratory infectious agent detection by nucleic acid (DNA and RNA), 18 viral types and subtypes |
| 0140U | Infectious disease (fungi), fungal pathogen identification, DNA (15 fungal targets), blood culture |
| 0141U | Infectious disease (bacteria and fungi), gram-positive organism identification and drug resistance |
| 0142U | Infectious disease (bacteria and fungi), gram-negative bacterial identification and drug resistance |
| 0152U | Infectious disease (bacteria, fungi, parasites, and DNA viruses), DNA, PCR and next-generation sequencing |
| 0202U | Infectious disease (bacterial or viral respiratory tract infection), pathogen-specific nucleic acid |
| 0223U | Infectious disease (bacterial or viral respiratory tract infection), pathogen-specific nucleic acid |
| 0225U | Infectious disease (bacterial or viral respiratory tract infection), pathogen-specific DNA and RNA, 22 targets |
| 0240U | Infectious disease (viral respiratory tract infection), pathogen-specific RNA, 3 targets |
| 0241U | Infectious disease (viral respiratory tract infection), pathogen-specific RNA, 4 targets |
| 0321U | Infectious agent detection by nucleic acid (DNA or RNA), genitourinary pathogens |
| 0323U | Infectious agent detection by nucleic acid (DNA and RNA), central nervous system pathogen, metagenomic |
| 0330U | Infectious agent detection by nucleic acid (DNA or RNA), vaginal pathogen panel, identification of 27 targets |
| 0352U | Infectious disease (bacterial vaginosis and vaginitis), multiplex amplified probe technique |
| 0369U | Infectious agent detection by nucleic acid (DNA and RNA), gastrointestinal pathogens, 31 bacterial targets |
| 0370U | Infectious agent detection by nucleic acid (DNA and RNA), surgical wound pathogens, 34 microorganisms |
| 0371U | Infectious agent detection by nucleic acid (DNA or RNA), genitourinary pathogen, semiquantitative |
| 0372U | Infectious disease (genitourinary pathogens), antibiotic-resistance gene detection, multiplex amplified probe |
| 0373U | Infectious agent detection by nucleic acid (DNA and RNA), respiratory tract infection, 17 bacteria |
| 0374U | Infectious agent detection by nucleic acid (DNA or RNA), genitourinary pathogens |
| 0441U | Infectious disease (bacterial, fungal, or viral infection), semiquantitative biomechanical assessment |
| 0442U | Infectious disease (respiratory infection), Myxovirus resistance protein A (MxA) and C-reactive protein |
| 0463U | Oncology (cervix), mRNA gene expression profiling of 14 biomarkers (E6 and E7 of highest-risk HPV) |
| 0480U | Infectious disease (bacteria, viruses, fungi, and parasites), cerebrospinal fluid (CSF), metagenomic |
| 0502U | Human papillomavirus (HPV), E6/E7 markers for high-risk types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68) |
| 0504U | Infectious disease (urinary tract infection), identification of 17 pathologic organisms, urine, real-time PCR |
| 0505U | Infectious disease (vaginal infection), identification of 32 pathogenic organisms, swab, real-time PCR |
| 0527U | Herpes simplex virus (HSV) types 1 and 2 and Varicella zoster virus (VZV), amplified probe technique |
| 0528U | Lower respiratory tract infectious agent detection, 18 bacteria, 8 viruses, and 7 antimicrobial-resistance genes |
| 0531U | Transcription for RNA targets, each analyte reported as detected or not detected with semiquantitative results |
| 0556U | Infectious disease (bacterial or viral respiratory tract infection), pathogen-specific DNA and RNA |
| 0557U | Infectious disease (bacterial vaginosis and vaginitis), real-time amplification of DNA markers |
| 0563U | Infectious disease (bacterial and/or viral respiratory tract infection), pathogen-specific nucleic acid |
| 0564U | Infectious disease (bacterial and/or viral respiratory tract infection), pathogen-specific nucleic acid |
| 0600U | Infectious disease (wound infection), identification of 65 organisms and 30 antibiotic resistance genes |
| 81513 | Infectious disease, bacterial vaginosis, quantitative real-time amplification of RNA markers for Atopobium vaginae |
| 81514 | Infectious disease, bacterial vaginosis and vaginitis, quantitative real-time amplification of DNA markers |
| 81515 | Infectious disease, bacterial vaginosis and vaginitis, real-time PCR amplification of DNA markers |
| 87480 | Candida species, direct probe technique |
| 87481 | Candida species, amplified probe technique |
| 87482 | Candida species, quantification |
| 87483 | Central nervous system pathogen (e.g., Neisseria meningitidis) |
| 87490 | Chlamydia trachomatis, direct probe technique |
| 87491 | Chlamydia trachomatis, amplified probe technique |
| 87492 | Chlamydia trachomatis, quantification |
| 87494 | Chlamydia trachomatis and Neisseria gonorrhoeae |
| 87505 | Gastrointestinal pathogen panel, direct probe technique |
| 87506 | Gastrointestinal pathogen panel, amplified probe technique |
| 87507 | Gastrointestinal pathogen panel, quantification |
| 87510 | Gardnerella vaginalis, direct probe technique |
| 87511 | Gardnerella vaginalis, amplified probe technique |
| 87512 | Gardnerella vaginalis, quantification |
| 87528 | Herpes simplex virus, direct probe technique |
| 87529 | Herpes simplex virus, amplified probe technique |
| 87530 | Herpes simplex virus, quantification |
| 87590 | Neisseria gonorrhoeae, direct probe technique |
| 87591 | Neisseria gonorrhoeae, amplified probe technique |
| 87592 | Neisseria gonorrhoeae, quantification |
| 87623 | Human Papillomavirus (HPV), low-risk types |
| 87624 | Human Papillomavirus (HPV), high-risk types |
| 87625 | Human Papillomavirus (HPV), types 16 and 18 only |
| 87626 | Human Papillomavirus (HPV), separately reported types |
| 87631 | Respiratory virus, 3–5 targets |
| 87633 | Respiratory virus, 12–25 targets |
| 87636 | SARS-CoV-2 and influenza virus types A and B |
| 87637 | SARS-CoV-2, influenza A and B, and RSV |
| 87660 | Trichomonas vaginalis, direct probe technique |
| 87661 | Trichomonas vaginalis, amplified probe technique |
| 87797 | Infectious agent detection by nucleic acid, not otherwise specified; direct probe technique |
| 87798 | Infectious agent detection by nucleic acid, not otherwise specified; amplified probe technique |
| 87799 | Infectious agent detection by nucleic acid, not otherwise specified; quantification |
Key ICD-10-CM Diagnosis Codes (Selected from 453 Total)
| Code Range | Description |
|---|---|
| A50.01–A50.9 | Congenital syphilis |
| A51.0–A51.9 | Early syphilis |
| A52.00–A52.9 | Late syphilis |
| A53.0–A53.9 | Other and unspecified syphilis |
| A54.00–A54.9 | Gonococcal infection |
The full list of 453 ICD-10-CM codes spans bacterial STDs, viral STDs, fungal infections, genitourinary infections, CNS infections, respiratory infections, GI infections, skin and nail infections, and wound infections. Review the complete code list at the MM 0530 policy source to confirm your diagnosis code is included before billing.
Get the Full Picture for CPT 87490
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.